AI-generated research brief — verify at source
Ensitrelvir Fails to Improve Clinical Recovery in Hospitalized COVID-19 Adults Despite Antiviral Effect
In a phase 3 international randomized controlled trial, ensitrelvir added to standard of care did not improve clinical recovery over placebo in adults hospitalized with COVID-19, with no meaningful difference in the primary recovery scale score (median DRS-60: 6 vs. 5.5; OR 0.82, 95% CI 0.62–1.09; p=0.19). Although ensitrelvir reduced detectable viral antigen in plasma at Day 5, this virological signal did not translate into measurable clinical benefit.
What Was Studied
The trial investigated whether ensitrelvir, an oral 3CL protease inhibitor with potent antiviral activity, could improve clinical recovery when added to standard of care in adults hospitalized for COVID-19. The primary outcome was clinical recovery measured by the Days to Recovery Scale through Day 60 (DRS-60), a composite scale capturing the trajectory of illness resolution over a two-month follow-up period.
How It Was Studied
This was an international, randomized, double-blind, placebo-controlled phase 3 trial enrolling 589 hospitalized adults with COVID-19 between 2023 and 2025. Participants were assigned to receive either ensitrelvir plus standard of care (n=293) or placebo plus standard of care (n=296). The trial population had a median age of 69 years, was approximately half female, and predominantly White (68%). Standard of care was intensive and broadly similar between arms, with corticosteroids used in 61% and 54%, and remdesivir in 62% and 60% of the ensitrelvir and placebo groups, respectively. The primary endpoint was analyzed using a Van Elteren test, which accounts for stratification factors.
What Was Observed
- No statistically significant difference in clinical recovery was detected between groups. The median DRS-60 score was 6 (IQR 3–15) in the ensitrelvir arm versus 5.5 (IQR 3–12) in the placebo arm, with the odds of a better recovery category slightly favoring placebo (OR 0.82, 95% CI 0.62–1.09; p=0.19). The confidence interval spans values below and above 1.0, indicating the estimate is imprecise and consistent with no meaningful treatment effect.
- Ensitrelvir produced a clear virological effect: at Day 5, detectable viral antigen in plasma was nearly half as common in the ensitrelvir group compared to placebo (13.4% vs. 25.1%; p<0.001). Despite this significant reduction in viral burden, no corresponding improvement in secondary clinical outcomes was observed.
- Mortality was numerically higher in the ensitrelvir arm (6.1% vs. 4.4%), and hemorrhagic events were substantially more frequent among ensitrelvir-treated participants (3.4% vs. 0.3%). These imbalances were not formally adjudicated as statistically significant in the abstract but are clinically notable and warrant careful scrutiny.
Why This Matters
Antivirals remain a central pillar of severe COVID-19 management, and identifying agents that add meaningful benefit on top of existing effective therapies is a pressing clinical question. This trial demonstrates that a potent 3CL protease inhibitor capable of suppressing viral replication does not necessarily translate that antiviral activity into improved patient outcomes when background standard of care already includes remdesivir and corticosteroids. The findings raise substantive questions about whether additional antiviral agents can provide incremental clinical value in a treatment environment where baseline therapy is already optimized.
How to Read This Result
Although the trial is large, randomized, and of high methodological quality, the null clinical result must be interpreted in the specific context of Omicron-era disease severity and near-universal use of effective background therapies, which may have compressed the outcome space in ways that obscure any marginal benefit ensitrelvir could offer in higher-severity or less-treated populations.
Limitations
The trial was conducted during the Omicron phase of the pandemic, when hospitalized patients generally experienced lower baseline illness severity than in earlier waves, potentially reducing the room for detectable improvement. Furthermore, the high and balanced use of remdesivir and corticosteroids in both arms represents an already optimized standard of care that may have masked any additive benefit from ensitrelvir. These contextual factors limit the ability to draw conclusions about ensitrelvir’s utility in settings with less effective background treatment or higher-severity disease.